Melanotan-2 — questions, answered plainly.

Melanotan-2 is a synthetic cyclic seven-residue analogue of α-MSH that activates multiple melanocortin receptors, with significant MC3R and MC4R activity in addition to MC1R pigmentation effects. It is not approved as a medicine in any jurisdiction.

Melanotan-1 (afamelanotide) is a linear 13-residue α-MSH analogue with predominantly MC1R activity, FDA-approved for erythropoietic protoporphyria. Melanotan-2 is a smaller cyclic compound with broader melanocortin-receptor activity (especially MC4R), and it is not approved for human use.

No. PT-141 (bremelanotide) was derived from the Melanotan-2 scaffold but is a structurally distinct compound. PT-141 is FDA-approved as Vyleesi for premenopausal HSDD; Melanotan-2 is not approved anywhere.

Giuliano 2005 (Eur Urol, PMID 15967265) reported increased erectile activity in telemetry-monitored conscious rats. Wekwejt 2023 (Biomed Pharmacother, PMID 37478579) reported reversal of high-fat-diet memory impairment in zebrafish. Hjuler 2014 (Dermatology, PMID 24355990) is a single-patient case report of melanoma following Melanotan-II self-injection and tanning bed use.

Dermatology literature documents multiple case reports including melanoma association, dysplastic nevi, and acute nausea / vomiting / blood pressure changes in unregulated human use. The compound is sold widely through unregulated channels where purity, identity, and dose are not assured.

Melanotan-2 is not approved for human use in any jurisdiction. The published primary literature is dominated by preclinical animal pharmacology and adverse-event case reports rather than controlled human efficacy trials.